Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL9936743 | 0.88 | ADAMTS4 (0.53) | KMT2AMEN1TSHRADAMTS4MMP13 | |
| Cadaverine Tartrate SCHEMBL9938548 | 0.88 | KMT2A (0.55) | KMT2AMEN1ADAMTS4MMP13ALDH1A1 | |
| Cadaverine Tartrate SCHEMBL9938634 | 0.88 | KMT2A (0.53) | KMT2AMEN1ADAMTS4MMP13ALDH1A1 | |
| SCHEMBL196487 | 0.85 | KMT2A (0.70) | KMT2AMEN1ALDH1A1CYP2C9CYP2C19 | |
| Cadaverine Tartrate SCHEMBL3633165 | 0.83 | ADAMTS4 (0.48) | KMT2AMEN1ADAMTS4MMP13ALDH1A1 | |
| Cadaverine Tartrate SCHEMBL3634786 | 0.83 | PPARA (0.51) | KMT2AADAMTS4MMP13EPHX2PPARG | |
| SCHEMBL5801663 | 0.79 | KMT2A (0.65) | KMT2AMEN1ADAMTS4MMP13ALDH1A1 | |
| SCHEMBL12133623 | 0.76 | KMT2A (0.76) | KMT2AMEN1ALDH1A1RAB9APOLB | |
| SCHEMBL25542633 | 0.75 | KMT2A (0.59) | KMT2AMEN1ADAMTS4MMP13ALDH1A1 | |
| SCHEMBL5437522 | 0.75 | KDM4E (0.59) | KMT2AADAMTS4MMP13ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651403-A2 | USE OF LP-PLA2 INHIBITORS IN THE TREATMENT AND PREVENTION OF EYE DISEASES | Glaxo Group Limited (GB) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080497-A2 | METHODS OF TREATMENT AND PREVENTION OF EYE DISEASES | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | WO | disclosed |